Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practiceInés Suárez‐García, Julia Portilla, Belén Alejos et al.|Journal of Antimicrobial Chemotherapy|2023Cited by 36
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J. Fichtenbaum, Dushyantha Jayaweera, Kathleen V. Fitch et al.|The Journal of Infectious Diseases|2020Cited by 13
Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418Alfonso Cabello, Ignacio Valero, Alicia González Baeza et al.|Open Forum Infectious Diseases|2022Cited by 12
Incidence and Clinical, Virological, and Resistance Characteristics of HIV Infections Among pre-Exposure Prophylaxis Users in Spain (SCOPE Study): A Multicentre Prospective and Retrospective Cohort StudyMar Vera, Lucía Bailón, Patricia Álvarez-López et al.|The Lancet Regional Health - Europe|2026Cited by 0